

---

# Analytical Plan for Linear relationship between Maha stock price and the WTI oil price

DOCUMENT: SAP-2023-011-HM-v01

From: Felipe Figueiredo To: Henning

2023-03-08

## TABLE OF CONTENTS

1	ABBREVIATIONS.....	2
2	CONTEXT.....	2
	2.1 Objectives.....	2
	2.2 Hypotheses.....	2
3	DATA.....	2
	3.1 Raw data.....	2
	3.2 Analytical dataset.....	2
4	STUDY PARAMETERS.....	3
	4.1 Study design.....	3
	4.2 Inclusion and exclusion criteria.....	3
	4.3 Exposures.....	3
	4.4 Outcomes.....	3
	4.5 Covariates.....	3
5	STATISTICAL METHODS.....	4
	5.1 Statistical analyses.....	4
	5.1.1 Descriptive analyses.....	4
	5.1.2 Inferential analyses.....	4
	5.1.3 Statistical modeling.....	4
	5.1.4 Missing data.....	4
	5.2 Significance and Confidence Intervals.....	4
	5.3 Study size and Power.....	4
	5.4 Statistical packages.....	4
6	OBSERVATIONS AND LIMITATIONS.....	4
7	REFERENCES.....	5
8	APPENDIX.....	5
	8.1 Availability.....	5

---

---

# Analytical Plan for Linear relationship between Maha stock price and the WTI oil price

## Document version

Version	Alterations
01	Initial version

## 1 ABBREVIATIONS

- CI: confidence interval
- SD: standard deviation

## 2 CONTEXT

### 2.1 Objectives

To evaluate the strength of the linear relationship between Maha stock price and the WTI oil price.

### 2.2 Hypotheses

Maha stock price changes are linearly dependent on WTI oil price changes.

## 3 DATA

### 3.1 Raw data

The original data base had 3 variables collected on 21 observations.

### 3.2 Analytical dataset

After the cleaning process 4 variables were included in the analysis. The total number of observations excluded due to incompleteness and exclusion criteria will be reported in the analysis. Table 1 shows the structure of the analytical dataset.

## Analytical Plan (SAP)

**Table 1** Analytical dataset structure after variable selection and cleaning.

id	day	maha	wti
1			
2			
3			
...			
N			

All variables in the analytical set were labeled according to the raw data provided and values were labeled according to the data dictionary for the preparation of production-quality results tables and figures.

## 4 STUDY PARAMETERS

### 4.1 Study design

Cross-sectional.

### 4.2 Inclusion and exclusion criteria

N/A

### 4.3 Exposures

WTI oil price change in percent.

### 4.4 Outcomes

**Specification of outcome measures** (Zarin, 2011):

1. (Domain) Capital markets
2. (Specific measurement) Maha stock price change
3. (Specific metric) End-value
4. (Method of aggregation) Average

#### Primary outcome

Maha stock price change in percent.

### 4.5 Covariates

N/A

## 5 STATISTICAL METHODS

### 5.1 Statistical analyses

#### 5.1.1 Descriptive analyses

Price changes will be described as mean (SD). The distributions of price changes' characteristics will be summarized in tables and visualized in exploratory plots.

#### 5.1.2 Inferential analyses

All inferential analyses will be performed in the statistical models (described in the next section).

#### 5.1.3 Statistical modeling

An explanatory linear regression model will be fitted to investigate how much the WTI price change explain the changes in Maha stock prices.

#### 5.1.4 Missing data

No missing data imputation will be performed. All evaluations will be performed as complete case analyses. Missing data counts and proportions will be reported in tables.

### 5.2 Significance and Confidence Intervals

All analyses will be performed using the significance level of 5%. All significance hypothesis tests and confidence intervals computed will be two-tailed.

### 5.3 Study size and Power

N/A

### 5.4 Statistical packages

This analysis will be performed using statistical software R version 4.2.1.

## 6 OBSERVATIONS AND LIMITATIONS

N/A

## 7 REFERENCES

- **SAR-2023-011-HM-v01** – Linear relationship between Maha stock price and the WTI oil price
- Zarin DA, et al. The ClinicalTrials.gov results database – update and key issues. N Engl J Med 2011;364:852-60 (<https://doi.org/10.1056/NEJMsa1012065>).
- Gamble C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337–2343 (<https://doi.org/10.1001/jama.2017.18556>).

## 8 APPENDIX

This document was elaborated following recommendations on the structure for Statistical Analysis Plans (Gamble, 2017) for better transparency and clarity.

### 8.1 Availability

All documents from this consultation were included in the consultant's Portfolio.

The portfolio is available at:

<https://philsf-biostat.github.io/SAR-2023-011-HM/>